Negara: Irlandia
Bahasa: Inggris
Sumber: HPRA (Health Products Regulatory Authority)
CANDESARTAN CILEXETIL
B & S Healthcare
CANDESARTAN CILEXETIL
8 Milligram
Tablets
Product subject to prescription which may be renewed (B)
Authorised
0000-00-00
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Atacand 8 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 8 mg candesartan cilexetil. Excipients: Lactose For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. _Product imported from the UK:_ Pale pink, round tablets with a scoreline on both sides. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Atacand is indicated for the: Treatment of essential hypertension in adults. Treatment of adult patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction 40%) as add-on therapy to Angiotensin Converting Enzyme (ACE) inhibitors or when ACE inhibitors are not tolerated (see section 5.1 Pharmacodynamic properties). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology in Hypertension The recommended initial dose and usual maintenance dose of Atacand is 8mg once daily. Most of the antihypertensive effect is attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 16mg once daily and to a maximum of 32mg once daily. Therapy should be adjusted according to blood pressure response. Atacand may also be administered with other antihypertensive agents. Addition of hydrochlorothiazide has been shown to have an additive antihypertensive effect with various doses of Atacand. _Elderly population_ No initial dosage adjustment is necessary in elderly patients. _Patients with intravascular volume depletion_ An initial dose of 4mg may be considered in patients at risk for hypotension, such as patients with possible volume depletion (see also 4.4 Special warnings and special precautions for use). _Patient with renal impairment_ The starting dose is 4 mg in patients with renal i Baca dokumen lengkapnya